March 1st, 2022, Chongqing · China – Porton Pharma Solutions Ltd. announced an investment of 420 million to expand CDMO Production Capacity of Small Molecule API in Porton Pharma (Jiangxi) Co., Ltd. which is mainly engaged in customized production of APIs, intermediates and starting materials.

This expansion project will add 2 production workshops, utilities workshop, comprehensive warehouses and other facilities, which total construction area is 31,270㎡. With an estimated new production capacity of 300 m3, it is planned to be completed and put into operation by the end of 2023. In the future, Porton will undertake more high value-added intermediates and API production projects, which will help further consolidate the company’s comprehensive capabilities as an End-to-End CDMO service platform.